Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety - Wikidata - wikimedia - TriplyDB

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

http://www.wikidata.org/entity/Q33405602

about

Current Trends of Renal Impairment in Multiple Myeloma Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trials From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma Targeted treatments for multiple myeloma: specific role of carfilzomib New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma Clinical use of proteasome inhibitors in the treatment of multiple myeloma Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary re Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells European Myeloma Network guidelines for the management of multiple myeloma-related complications.Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.Carfilzomib: a novel agent for multiple myeloma.Kidney disease and multiple myeloma.International Myeloma Working Group recommendations for global myeloma care.Future agents and treatment directions in multiple myeloma.Current strategies for treatment of relapsed/refractory multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.New drugs in multiple myeloma - role of carfilzomib and pomalidomide.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.Salvage therapy of multiple myeloma: the new generation drugs.Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.Carfilzomib in multiple myeloma.

P2860

Q26740444-77D37F24-C842-4563-A679-70B76DCA40F9 Q26741620-41CB264D-F857-4CFE-990B-6A023185D7F4 Q26862828-50E312F3-47D7-444D-9162-E2E45B6F2A25 Q26996524-976BA016-007A-42E6-8040-9352288A7AF3 Q27004421-825A74D1-210D-4739-A20B-545B23CFF784 Q27014143-D1120681-3ADE-47DB-822C-3D85837C37A6 Q28067148-74D8FD70-C79F-4FD3-AEC6-A2C9A825FBF4 Q28080999-A17CDB90-C169-498D-9452-8C1CA6244416 Q28084683-49FAF9C2-AC1D-49EC-8A9F-F73051496418 Q30238893-92C57E98-2264-4351-BA23-A5648B48D33C Q30491777-C61D7CAC-4ECD-4C87-939A-469A6D4BD4A4 Q33409681-B614DF09-0C06-45E5-BDC0-82FE9C813E33 Q33410213-3227B490-7A47-479D-9206-B0C4BAA09FF0 Q33416105-BB26271C-7D9C-4AFC-8730-016A5A169F00 Q33429346-2E78AE77-A741-4CA6-BC2A-23A38AE35D4E Q33430690-14D7364F-29FA-4E62-A7FF-99938FA511E1 Q33433893-27D5AC40-E365-4C3E-AD64-1DE054BB7F2D Q33710330-2E7C5798-9CD4-4A87-B447-5BEE3E0FC507 Q34893956-624B2F3A-BA2E-4BD0-AC4F-1D45A712141C Q35509621-E14D9603-11A8-4F38-8203-4BA453DEE4A3 Q36020680-0502E283-7B52-41D1-B790-AEBA3E59F1D9 Q36098363-12CBA579-CE2F-4647-AC2C-4BA2B9337CC1 Q36115636-051A25AB-3362-4E46-A72D-38116F4B0EE0 Q36178810-38BF255C-A714-4DF9-B885-D68470BDF9C9 Q36595921-57E1BD18-D29E-4787-8CE5-CA4E7D648BF7 Q37375516-FF2AF550-CF58-49D4-974B-89F55FFE838C Q37397995-E8353BD4-39FC-4821-8FEF-17B4179C2895 Q38120296-B0B5A861-C1B7-456D-A0F7-0A9A07EF0F32 Q38122674-2B72B216-7784-472D-8467-31C4034D4407 Q38157532-E9EFEEED-BAC1-41D0-A6F6-6D546C5E4262 Q38172300-2911859C-2C1D-480C-83D7-3BD270E161B7 Q38182683-3ADB7646-4877-42C5-823A-5366916C70F4 Q38187476-EC1674C5-2EF2-4FB5-8700-50F2E02D357F Q38216018-3DAA8E47-4A81-41DD-AAC2-39E6979EFB99 Q38218209-303D3883-D169-4EF6-B4C6-79E3B3F62933 Q38223433-0D44FC37-A2F4-4AB6-A15A-E14F629744D1 Q38224422-A7660498-4AAC-4838-ACFF-D277716820E3 Q38227506-4E5A575B-680C-4423-86B7-15E00A5DF450 Q38231991-01A010C3-3B4F-4F60-97FB-7B52898AD077 Q38244558-223969B7-A197-48DA-B0F0-D4552D92D9B3

P2860

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

http://www.wikidata.org/entity/Q33405602

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Carfilzomib in multiple myelom ...... t: pharmacokinetics and safety

@ast

Carfilzomib in multiple myelom ...... t: pharmacokinetics and safety

@en

type

label

Carfilzomib in multiple myelom ...... t: pharmacokinetics and safety

@ast

Carfilzomib in multiple myelom ...... t: pharmacokinetics and safety

@en

prefLabel

Carfilzomib in multiple myelom ...... t: pharmacokinetics and safety

@ast

Carfilzomib in multiple myelom ...... t: pharmacokinetics and safety

@en

P1433

Q33405602-36B39636-8442-4D11-A18F-8F683C6EAF25

P1476

Q33405602-2F5C1460-4149-41B4-AE17-EA3DD9BDA582

P2093

Q33405602-12D509D5-6E2B-4C1C-96C6-CEDF3DAA1C05

Q33405602-27585220-4D5E-4FC4-8AE3-1BB555ADD17C

Q33405602-2C73C5EA-8B75-4802-B063-2AAD3CB5D594

Q33405602-2DD6F4DD-1B1E-4B01-AAC8-DAD156909385

Q33405602-4D7D26DC-C12B-4976-97DB-6F08D3205138

Q33405602-56ACEE44-4AD7-4294-8FF9-366DD825EBC1

Q33405602-5A8F9C0B-023E-4621-ACE2-67D9BC09601F

Q33405602-70DD0C22-53DE-4D0D-A410-9B80565E29AF

Q33405602-E99A7E6D-5DBD-4936-BDE9-B87F408AA65B

P2860

Q33405602-083F27D9-7A1A-44E3-B73F-EDBB274269FA

Q33405602-1069E7C9-858A-4589-9859-CC3913CE318D

Q33405602-1E1B976A-B624-4941-9A43-17F4C3A0C509

Q33405602-1F88E75C-8FA6-4DEE-8D78-583C94317BBC

Q33405602-23F5F0AD-C37C-4BFF-868B-581FD4F52505

Q33405602-259CC276-66CA-488B-95BC-09D0A43401F5

Q33405602-293232F6-5EDA-4DF1-AF51-3F14E3C6B537

Q33405602-3A54811D-A41C-45C7-B054-523AD4C245C8

Q33405602-53BC7462-AAC8-4341-842C-1518ECC95663

Q33405602-68352915-CF8E-47FE-A22E-536CF83D31EE

P2888

Q33405602-E9B9C817-60F9-4AD4-9695-3DC960D2E602

P304

Q33405602-A9E5FF55-D3C0-4E40-9E91-BADB2787EDB4

P31

Q33405602-3975F851-2454-454F-A759-6717B7BCE93A

P356

Q33405602-CFE83879-4999-4C54-8C94-6789C359723C

P433

Q33405602-C9E00DF7-3859-4FEE-83C2-4B935CE4FE8B

P478

Q33405602-DABD1A02-5D5E-4A2B-AE7B-385DFB2F1E84

P577

Q33405602-3DF06359-1FD0-4D06-995F-A8F28D84B867

P5875

Q33405602-279481E1-1917-443F-9397-C8A3ECD29097

P6179

Q33405602-A38DE169-2F9D-4602-A584-BA2E1565D938

P698

Q33405602-541C52CF-0476-4788-BE5B-8F82F5318744

P932

Q33405602-7735AB71-7151-41C2-81E1-B2721BA59E7C

P356

P1433

P1476

Carfilzomib in multiple myelom ...... t: pharmacokinetics and safety

@en

P2093

A F Wong

http://www.w3.org/2001/XMLSchema#string

A Z Badros

http://www.w3.org/2001/XMLSchema#string

J A Zonder

http://www.w3.org/2001/XMLSchema#string

L Kunkel

http://www.w3.org/2001/XMLSchema#string

R Niesvizky

http://www.w3.org/2001/XMLSchema#string

R Vij

http://www.w3.org/2001/XMLSchema#string

S Lee

http://www.w3.org/2001/XMLSchema#string

T Martin

http://www.w3.org/2001/XMLSchema#string

Z Wang

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

International uniform response criteria for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Review of 1027 patients with newly diagnosed multiple myeloma.

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

P2888

P304

1707-1714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.29

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235385803

http://www.w3.org/2001/XMLSchema#string

P6179

1023785372

http://www.w3.org/2001/XMLSchema#string

P698

23364621

http://www.w3.org/2001/XMLSchema#string

P932

3740399

http://www.w3.org/2001/XMLSchema#string